Part of the investment will be spent on a new commercial drug product manufacturing facility in Bethlehem, Pennsylvania
Lubrizol LifeSciences is expanding its global facilities for
excipients, polymers and contract manufacturing
Lubrizol Corporation is investing in its key capabilities through a variety of planned expansions in its LifeSciences business. This includes a US$60 million investment to strengthen the excipients, polymers, drug formulation and manufacturing, and medical device contract manufacturing capabilities at Lubrizol LifeSciences’ global facilities.
Commercial drug product manufacturing will be added at the company’s Particle Sciences facility in Bethlehem, Pennsylvania. Utilising the company’s knowledge in complex formulations and production, the facility will be adjacent to the existing development and clinical trial manufacturing site, offering customers a seamless flow from development through manufacturing.
The new space, which is expected to be operational in the fourth quarter of 2017, will accommodate both sterile and non-sterile products, highly potent compounds, and organic solvent processing.
Additionally, LifeSciences is investing to expand its global facilities for excipients, polymers and contract manufacturing, with a focus on quality and efficiency.
This capital investment will impact multiple sites to increase in-house engineering capacity across the LifeSciences portfolio of medical and pharmaceutical applications. This includes new investments in design, manufacturing and sterilisation technologies for the production of interventional catheters and long-term implantable devices, an area of strategic importance to the medical device segment.
"We have significantly enhanced our capabilities through the combination of strong polymer technology, application know-how and world-class manufacturing," said Deb Langer, vice president, Lubrizol Personal Home and Health Care. "As healthcare companies look for total solution providers, we continue to invest in the right areas to provide valuable offerings where our customers are experiencing the most growth."
Lubrizol LifeSciences has an in-depth understanding of functional polymer systems, combined with a portfolio of specialty materials, which enables it to deliver application-specific, quality solutions to the medical device and pharmaceutical industries.
With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world.